Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163915 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02163915 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 47 participants.
The verdict
NCT02163915, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
Interventions
- DRUG TAK-137
- DRUG TAK-137 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02163915
The ClinicalTrials.gov registry entry for NCT02163915 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-137 is the first listed.
NCT02163915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02163915 about?
NCT02163915 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.". The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
What is the current status of trial NCT02163915?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2014-06. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02163915?
The interventions under investigation include: TAK-137 (DRUG), TAK-137 Placebo (DRUG).
Who is sponsoring clinical trial NCT02163915?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.